PEP Metabolite Inhibits cGAS-STING to Slow Aging Inflammation

SNIPPET: Phosphoenolpyruvate (PEP), a glycolytic metabolite, directly inhibits the cGAS-STING inflammatory pathway by competitively binding to cGAS, preventing DNA-triggered immune activation. Published in Nature Aging (March 2026), Song et al. show PEP follows a biphasic trajectory during aging — rising early, then collapsing — and that supplementing PEP before its decline promotes healthspan and lifespan in mice.

THE PROTOHUMAN PERSPECTIVE#

The body is not a passive victim of aging. That sentence matters more than most of what gets written in longevity circles. What Song et al. have uncovered is evidence that metabolism itself builds temporary firewalls against inflammatory decay — and that those firewalls have an expiration date.

PEP is not a supplement you can buy. It's a molecule your glycolytic machinery already produces. The finding that it accumulates early in aging as a protective response — only to eventually collapse, unleashing cGAS-STING-driven inflammaging — reframes how we think about the aging trajectory. This isn't entropy. It's a defense system that runs out of resources.

For those of us who track the intersection of metabolism and immune aging, this study lands differently than most. It tells us the body was already trying to solve the inflammaging problem. It just couldn't sustain the solution. The question now is whether we can extend that window — and that's worth paying attention to on a decade-level timescale.

THE SCIENCE#

What Is PEP and Why Should You Care?#

Phosphoenolpyruvate is a high-energy intermediate in glycolysis — the metabolic pathway that breaks glucose into pyruvate. It sits near the end of the glycolytic chain, one step before pyruvate kinase converts it to pyruvate. Most biochemistry textbooks treat it as a waypoint. Song et al. argue it's much more than that^[1].

PEP is an endogenous inhibitor of the cGAS-STING pathway — the innate immune sensing system that detects cytoplasmic DNA and triggers inflammatory signaling. This pathway, when chronically activated by age-related DNA damage and mitochondrial dysfunction, is a primary driver of inflammaging and neurodegeneration^[2][3].

The data tells a specific story: PEP competitively binds to cGAS, physically preventing the enzyme from binding to DNA. No DNA binding means no cGAMP synthesis, no STING activation, no downstream interferon response. It's an elegant molecular brake.

The Biphasic Trajectory#

Here's what the data actually showed. Longitudinal analyses in both mice and humans revealed that PEP levels follow a biphasic curve during aging: they rise in early-to-middle aging, then progressively decline with advanced age^[1].

That initial rise? It appears to be adaptive. The body is producing more PEP to counteract the increasing activation of cGAS-STING as DNA damage accumulates. The decline that follows is where things go wrong.

When Song et al. blocked PEP accumulation in mice, inflammation accelerated and aging phenotypes worsened. When they administered PEP exogenously before the natural decline window (starting at 20 months of age in mice — roughly equivalent to late middle age in humans), the treated animals showed reduced inflammatory markers in plasma, liver, kidney, and brain tissue over a 6-month supplementation period^[1].

The magnitude matters. PEP-treated mice showed reduced senescence-associated β-galactosidase staining in lung and brain tissue, lower immune cell infiltration in liver and kidney, and improved performance on grip strength and Y-maze cognitive tests compared to vehicle-treated controls (n = 8 per group)^[1].

The cGAS Binding Mechanism#

The mechanistic work is where this paper earns its credibility. Using pull-down assays with PEP-coupled Sepharose beads and quantification of cGAS foci in THP-1 cells, Song et al. demonstrated that PEP directly disrupts the cGAS-DNA complex^[1].

In THP-1 cells transfected with HT-DNA, PEP treatment significantly reduced cGAS foci formation (n = 3). LC-MS analysis of senescent WI-38 cells treated with PEP showed altered glycolytic metabolite profiles, but the anti-inflammatory effect was independent of PEP's metabolic role in glycolysis — it was the direct physical binding to cGAS that mattered^[1].

Cytokine-array analysis of replication-induced senescent WI-38 cells confirmed that PEP treatment reduced the secretion of multiple inflammatory factors associated with the senescence-associated secretory phenotype (SASP)^[1]. This is significant. SASP is one of the primary mechanisms by which senescent cells poison their neighbors and propagate tissue dysfunction.

I'll be direct: the sample sizes in some of these mechanistic experiments were small (n = 2 for cytokine arrays, n = 3 for several cell-based assays). The in vivo work is stronger at n = 8 per group, but I'd want to see this replicated in independent labs before drawing firm conclusions about translational potential.

The Alzheimer's Connection#

PEP supplementation also ameliorated pathology in 5×FAD mice, an Alzheimer's disease model^[1]. Given that Gulen et al. (2023) previously established that cGAS-STING drives aging-related neuroinflammation and neurodegeneration^[3], this finding is mechanistically coherent — suppress the upstream trigger, and you'd expect downstream neuroprotection.

But here's where it gets complicated. The 5×FAD model is a transgenic system with aggressive amyloid pathology. Translating results from this model to human Alzheimer's disease has a notoriously poor track record. The mechanism is plausible. The clinical relevance remains unproven.

Human Correlation Data#

In aged human subjects, high circulating PEP levels correlated strongly with lower inflammatory markers and healthier phenotypic indicators^[1]. This is correlational, not causal, and the study authors are appropriately careful about that distinction. But the correlation across species — mice and humans showing the same biphasic PEP trajectory — strengthens the case that this is an evolutionarily conserved mechanism.

The commentary by Wang and Zeng in Nature Aging frames this as a "two-hit model" of cGAS-driven aging: the first hit is accumulating DNA damage activating cGAS, and the second hit is the collapse of the PEP brake that had been holding inflammaging in check^[2]. That framing is useful.

COMPARISON TABLE#

THE PROTOCOL#

This is where I have to be honest: PEP is not a consumer supplement. It is a phosphorylated glycolytic intermediate that is not currently available in any commercial supplement form, and oral bioavailability of phosphorylated metabolites is generally poor. The study administered PEP systemically in mice.

That said, the underlying biology points toward actionable strategies for supporting endogenous PEP production and limiting cGAS-STING overactivation.

Step 1. Maintain glycolytic flux through regular aerobic exercise. PEP is a direct product of glycolysis, and consistent moderate-intensity exercise (150-300 minutes per week of zone 2 cardio) supports healthy glycolytic metabolism. The goal is metabolic efficiency, not exhaustion.

Step 2. Prioritize glucose disposal capacity. Insulin resistance impairs glycolytic throughput. Strategies that improve insulin sensitivity — strength training, time-restricted eating (12-16 hour feeding windows), and maintaining healthy body composition — may indirectly support PEP production.

Step 3. Consider existing cGAS-STING modulators while waiting for PEP-specific interventions. Low-dose aspirin has shown some capacity to inhibit cGAS activity in preclinical models. Discuss with a physician if this fits your risk profile.

Step 4. Monitor inflammatory biomarkers longitudinally. High-sensitivity CRP (hs-CRP), IL-6, and TNF-α are proxies for the inflammaging burden that PEP appears to counteract. Track these annually or biannually through standard blood panels.

Step 5. Support mitochondrial integrity. Mitochondrial DNA leakage into the cytoplasm is a primary trigger for cGAS-STING activation. Compounds that support mitochondrial membrane potential — CoQ10 (100-200 mg/day), urolithin A (500-1000 mg/day based on emerging trial data), and adequate magnesium intake (400-600 mg/day) — may reduce the upstream trigger.

Step 6. Watch this space. If PEP or PEP-mimetic compounds enter clinical development, early-phase trials will likely target individuals with elevated inflammaging markers. Getting baseline measurements now positions you for informed participation later.

What is phosphoenolpyruvate (PEP) and how does it relate to aging?#

Phosphoenolpyruvate is a high-energy metabolite produced during glycolysis, the fundamental pathway that converts glucose to energy. According to Song et al. (2026) in Nature Aging, PEP directly binds to the cGAS enzyme, preventing it from triggering the inflammatory cGAS-STING signaling cascade that drives age-related chronic inflammation. PEP levels rise during early aging as an apparent protective adaptation, then decline with advanced age — coinciding with accelerated inflammaging.

Can you take PEP as a supplement right now?#

No. PEP is a phosphorylated metabolite with no established oral bioavailability in humans, and it is not available as a commercial dietary supplement. The mouse studies administered PEP systemically (likely via injection). Any future human application would require either a novel delivery method, a PEP-mimetic drug, or strategies to boost endogenous PEP production.

How does the cGAS-STING pathway cause aging?#

The cGAS-STING pathway is an innate immune sensor that detects cytoplasmic DNA — which accumulates during aging due to mitochondrial dysfunction, DNA damage, and cellular senescence. Once activated, it triggers interferon signaling and pro-inflammatory cytokine release, contributing to the chronic low-grade inflammation known as inflammaging. Gulen et al. (2023) established in Nature that this pathway directly drives age-related neurodegeneration^[3].

Why is the biphasic PEP trajectory important?#

The biphasic pattern — PEP rises, then falls — suggests the body mounts a metabolic defense against inflammaging that eventually fails. This challenges the assumption that all metabolic changes during aging are harmful. Understanding when PEP levels collapse could define a critical intervention window for anti-aging therapies.

Who would benefit most from future PEP-based therapies?#

Based on the current data, individuals entering late middle age (roughly 50-65 in human terms, extrapolating from the 20-month mouse timepoint) with rising inflammatory markers may be the optimal target population. The study also suggests particular relevance for neurodegenerative conditions, given the improvements observed in the Alzheimer's disease mouse model.

VERDICT#

Score: 8/10

This one actually moved me. The mechanistic elegance is real — a glycolytic metabolite that moonlights as an innate immune checkpoint is the kind of finding that reframes how we think about metabolism and aging. Published in Nature Aging with both mouse in vivo and human correlational data, the evidence is strong for a preclinical study.

The limitations are equally real. Some mechanistic experiments had minimal sample sizes. The in vivo work used n = 8 per group — adequate for mouse studies but not overwhelming. The human data is correlational only. And the translation gap between systemic PEP administration in mice and a viable human intervention remains wide.

But the core insight — that the body builds and then loses a metabolic brake on inflammaging — is genuinely new. It shifts the conversation from "how do we stop damage" to "how do we sustain the defense systems that were already working." That's a more interesting question, and this study gives us a molecular handle on it.

I'm not changing my protocol based on this paper alone. But I'm watching every follow-up closely.